SenesTech

SenesTech, Inc. engages in the development and commercialization of proprietary technology for the management of animal pest populations, primarily rat populations through fertility control. It offers its ContraPest product to residential, and commercial sectors such as animal, structural, and food markets. The company was founded by Loretta P. Mayer and Cheryl A. Dyer on July 27, 2004 and is headquartered in Phoenix, AZ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SenesTech reports record revenue growth driven by Evolve product launch

SenesTech's Q1 2024 performance was driven by the successful launch of Evolve, leading to record revenue growth. The company's strengths lie in expanding distribution channels and focusing on operational efficiencies. Challenges include achieving positive cash flow and balancing sales channels, while opportunities exist in capturing a larger market share with Evolve mouse and leveraging the Amazon store launch.

SenesTech achieves record revenue and margin growth, eyes global expansion

SenesTech delivered strong financial performance with record revenue and improved margins.
The company's product portfolio and expansion strategies position it for continued growth.
Challenges include maintaining profitability, managing competition, and balancing growth with financial stability.
Opportunities exist in market penetration, partnerships, and global expansion initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SenesTech, Inc. engages in the development and commercialization of proprietary technology for the management of animal pest populations. The firm focuses on rat populations through fertility control. It offers its ContraPest product to residential and commercial sectors such as animal, structural, and food markets. The company was founded by Loretta P. Mayer and Cheryl A. Dyer on July 27, 2004 and is headquartered in Phoenix, AZ.

Product Sales Break $1 Million Sales Increase 77% for the Year PHOENIX , March 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"),  (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2022 financial results, with products sales increasing 77% compared to the prior year. Joel Fruendt, SenesTech's new Chief Executive Officer, commented, "Breaking $1 million is a tremendous milestone.

SenesTech Announces 2022 Financial Results

PHOENIX , March 14, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today confirmed news reports that the Company has been working with the Danish company TriptoBIO on the development of biosynthetic triptolide, one of the active ingredients in ContraPest. "We have been working with TriptoBIO for quite some time on biosynthetic triptolide, and have a letter of intent in place for its development and will be working collaboratively to have it approved by the EPA," said Joel Fruendt, SenesTech's CEO.

SenesTech Working with TriptoBIO on Biosynthetic Triptolide

Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX , March 8, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its fourth quarter and fiscal year 2022, ended December 31, 2022, after the market close on Thursday, March 16, 2023. The Company has scheduled a conference call that same day, Thursday, March 16, 2023, at 5:00 pm ET, to review the results.

SenesTech to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Thursday, March 16, 2023

PHOENIX , Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts.

SenesTech Names Nicole Williams as Chief Revenue Officer

PHOENIX , Jan. 24, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today announced the management team will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 9:00am ET on Tuesday, January 31, 2023, on the Company's website at https://senestech.investorroom.com/ or https://wsw.com/webcast/lytham7/snes/2054070.

SenesTech to Participate in the Lytham Partners Investor Select Conference

PHOENIX , Dec. 20, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the grant of inducement equity awards outside of the Company's 2018 Equity Incentive Plan to Joel Fruendt, its newly appointed Chief Executive Officer and two other newly hired employees. The grants were approved by the Compensation Committee of the Board of Directors as inducements material to Mr.

SenesTech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHOENIX , Nov. 18, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company") (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the closing of its previously announced public offering of 1,428,572 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 1,428,572 shares of its common stock ("Series A Warrants"), and Series B warrants to purchase up to 1,428,572 shares of its common stock ("Series B Warrants", together with Series A Warrants, collectively the "Series Warrants"), at an offering price to the public of $3.50 per share (or pre-funded warrant in lieu thereof) and associated Series Warrants. The Series A Warrants have an exercise price of $3.165 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

SenesTech, Inc. Announces Closing of $5 Million Public Offering

PHOENIX , Nov. 16, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company") (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the pricing of a public offering of up to 1,428,572 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 1,428,572 shares of its common stock ("Series A Warrants"), and Series B warrants to purchase up to 1,428,572 shares of its common stock ("Series B Warrants", together with Series A Warrants, collectively the "Series Warrants"), at an offering price to the public of $3.50 per share (or pre-funded warrant in lieu thereof) and associated Series Warrants. The Series A Warrants will have an exercise price of $3.165 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

SenesTech, Inc. Announces Pricing of $5 Million Public Offering

SenesTech (SNES) announced that it intends to effect a reverse stock split. These are the details.

SenesTech (SNES) Stock: 1-For-20 Reverse Split Declared

SenesTech, Inc. (NASDAQ:SNES ) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Robert Blum - Managing Partner-Lytham Partners Ken Siegel - Chief Executive Officer Joel Fruendt - Incoming Chief Executive Officer Tom Chesterman - Chief Financial Officer Conference Call Participants Amit Dayal - H.C. Wainwright Operator Good day, and welcome to the SenesTech Incorporated Reports Third Quarter of 2022 Financial Results Conference Call.

SenesTech, Inc. (SNES) Q3 2022 Earnings Call Transcript

Senestech, Inc. (SNES) delivered earnings and revenue surprises of -4.76% and 40.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Senestech, Inc. (SNES) Reports Q3 Loss, Misses Revenue Estimates

Product Sales up 57% year-over-year PHOENIX , Nov. 14, 2022  /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"),  (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced third quarter 2022 financial results, with products sales increasing 57% compared to the third quarter of the prior year. "We continue to make progress in the deployment of ContraPest across a wide variety of industry verticals with particularly strong growth from our e-commerce platform," commented Ken Siegel, SenesTech's Chief Executive Officer.

SenesTech Announces Third Quarter 2022 Financial Results

PHOENIX , Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period.

SenesTech Announces Appointment of Vector and Pest Control Industry Veteran Joel Fruendt as Chief Executive Officer

Financial results to be released before market open; Conference call to be conducted at 11:00 am ET PHOENIX , Nov. 9, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its third quarter 2022, ended September 30, 2022, before the market open on Monday, November 14, 2022. The Company has scheduled a conference call that same day, Monday, November 14, 2002, at 11:00 am ET, to review the results.

SenesTech to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Kintara Therapeutics

Microvast Holdings

RedHill Biopharma

Can these penny stocks trading tips help your strategy? The post 3 Strategies for Buying and Selling Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Strategies for Buying and Selling Penny Stocks Right Now

PHOENIX , Sept. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

SenesTech to Participate in the Lytham Partners Fall 2022 Investor Conference

Intended to Facilitate a Reverse Stock Split, if Necessary PHOENIX , Aug. 26, 2022 /PRNewswire/ -- SenesTech, Inc.  (NASDAQ: SNES, "SenesTech" or the "Company") (www.senestech.com), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.001 per share, for each outstanding share of SenesTech common stock held of record on September 5, 2022.  The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company's common stock as a single class exclusively with respect to any proposal to adopt an amendment to the Company's certificate of incorporation to reclassify the outstanding shares of the Company's common stock into a smaller number of shares of such common stock at a ratio specified in or determined in accordance with the terms of any such amendment, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the foregoing matter, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

SenesTech Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

SenesTech, Inc. (NASDAQ:SNES ) Q2 2022 Earnings Confernece Call August 11, 2022 5:00 PM ET Company Participants Robert Blum – Managing Partner-Lytham Partners Ken Siegel – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Tucker Andersen – Above All Advisors Good afternoon, and welcome to the SenesTech Inc. Reports Second Quarter of Fiscal Year 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

SenesTech, Inc. (SNES) CEO Ken Siegel on Q2 2022 Results - Earnings Call Transcript

Senestech, Inc. (SNES) delivered earnings and revenue surprises of -10.53% and 24.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Senestech, Inc. (SNES) Reports Q2 Loss, Lags Revenue Estimates

Sales up 73% year-over-year and up 42% sequentially PHOENIX , Aug. 11, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced record second quarter 2022 product sales, with sales increasing 73% compared to the second quarter in the prior year, and up 42% sequentially from the first quarter of 2022. The second quarter represented a new quarterly record for SenesTech, with June being the highest revenue month ever.

SenesTech Announces Record Second Quarter 2022 Product Sales

Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX , Aug. 4, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its second quarter 2022, ended June 30, 2022, after the market close on Thursday, August 11, 2022. The Company has scheduled a conference call that same day, Thursday, August 11, 2022, at 5:00 pm ET, to review the results.

SenesTech to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

SenesTech, Inc. (NASDAQ:SNES ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Robert Blum – Managing Partner-Lytham Partners Ken Siegel – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Tucker Andersen – Above All Advisors Operator Good afternoon, and welcome to the SenesTech Reports First Quarter Fiscal Year 2022 Financial Results. All participants will be in a listen-only mode.

SenesTech's (SNES) CEO Ken Siegel on Q1 2022 Results - Earnings Call Transcript

Sales up 122% Company Launches New Elevate Bait System™ with ContraPest® PHOENIX , May 12, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"),  (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced record first quarter 2022 product sales, more than double compared to last year's first quarter. The Company continues to see strong growth from its recent marketing initiatives, including its award-winning "Operation Rat Race" campaign which has driven an increase in e-commerce sales, as well as accelerating close rates through its field sales team.

SenesTech Announces Record First Quarter 2022 Product Sales

Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX , May 5, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Thursday, May 12, 2022. The Company has scheduled a conference call that same day, Thursday, May 12, 2022, at 5:00 pm ET, to review the results.

SenesTech to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

PHOENIX , March 31, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022. The Company's webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website or at https://wsw.com/webcast/lytham4/snes/2050155.

News for SenesTech Stock (SNES)